retatrutide medication is one of the most exciting medications currently being studied for obesity and metabolic disease-but there's one important thing to understand: It is NOT approved yet. I get asked almost daily, “ Retatrutide FDA Approval Status 2026:

Using the five half-lives rule, it roughly takes 35 days (about five weeks) for the medication to be mostly eliminated

Sometimes were haggling over doses, says Dushay, who wrote about this topic in an op-ed for STAT in February

Our study emphasizes a potential association between insulin deficiency and SGLT2 inhibitor-associated hyDKA evidenced by high glucose levels and decreased C-peptide concentrations

Dive Brief: A dual-acting weight loss drug being developed by Roche helped people with obesity lose about 23 percentage points more of their body weight than those who received a placebo after 48 weeks of treatment in a Phase 2 trial, the company said late Monday

Butt, A